{"id":50303,"date":"2022-06-24T12:13:53","date_gmt":"2022-06-24T11:13:53","guid":{"rendered":"https:\/\/touchoncology.com\/?post_type=media_gallery&#038;p=50303"},"modified":"2022-06-24T16:20:26","modified_gmt":"2022-06-24T15:20:26","slug":"50303","status":"publish","type":"media_gallery","link":"https:\/\/touchoncology.com\/colorectal-cancer\/conference-hub\/50303\/","title":{"rendered":"Takayuki Yoshino, ASCO 2022: The impact of tumour location on prognosis in metastatic colorectal cancer"},"content":{"rendered":"<p><strong>Dr Takayuki Yoshino<\/strong> (National Cancer Center Hospital East, Chiba, Japan) discusses the findings from the phase 3 PARADIGM trial, which was part of a plenary session and selected as one of the top abstracts from the conference. The trial assessed panitumumab plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 as first-line treatment in patients with RAS wild-type metastatic colorectal cancer.<\/p>\n<p>Related video: <a href=\"https:\/\/touchoncology.com\/colorectal-cancer\/conference-hub\/takayuki-yoshino-asco-2022\/\">Takayuki Yoshino, ASCO 2022: PARADIGM trial of panitumumab plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 as first-line treatment in patients with MCRC<\/a><\/p>\n<p>The abstract \u2018<em>Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial<\/em>.\u2019 (<a href=\"https:\/\/meetings.asco.org\/abstracts-presentations\/208990\" target=\"_blank\" rel=\"noopener\">Abstract number LBA1<\/a>) was presented at the ASCO annual meeting, 3-7 June 2022.<\/p>\n<p><strong>Questions<\/strong><\/p>\n<ol>\n<li>What is the impact of tumour location on prognosis in metastatic colorectal cancer (mCRC)? (00:12-01:30)<\/li>\n<li>What was already known about the efficacy of initial treatment with panitumumab or bevacizumab plus mFOLFOX6 in the treatment of metastatic colorectal cancer? (01:30-02:58)<\/li>\n<\/ol>\n<p><strong>Disclosures:<\/strong> Takayuki Yoshino has nothing to disclose in relation to this video interview.<\/p>\n<p><strong>Support:<\/strong> Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.<\/p>\n<p><em>Filmed in coverage of the 2022 American Society of Clinical Oncology (ASCO) annual meeting.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dr Takayuki Yoshino (National Cancer Center Hospital East, Chiba, Japan) discusses the findings from the phase 3 PARADIGM trial, which was part of a plenary session and selected as one of the top abstracts from the conference. The trial assessed panitumumab plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 as first-line treatment in patients with RAS wild-type [&hellip;]<\/p>\n","protected":false},"featured_media":50300,"template":"","class_list":["post-50303","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-colorectal-cancer","video_categories-asco-highlights"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery\/50303"}],"collection":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":2,"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery\/50303\/revisions"}],"predecessor-version":[{"id":50305,"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery\/50303\/revisions\/50305"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media\/50300"}],"wp:attachment":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media?parent=50303"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}